Biocon Pharma gets FDA nod for arthritis drug Tofacitinib ER

Tofacitinib extended-release tablets are a Janus kinase inhibitor indicated for Rheumatoid Arthritis

BMS unveils new data highlighting sustained efficacy and safety of Sotyktu in psoriatic arthritis and lupus

Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions

AbbVie's Rinvoq beats Humira in key arthritis trial

The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor

Johnson & Johnson submits additional data to FDA on psoriatic arthritis

The submission is supported by results from the Phase 3b APEX study

Bristol Myers Squibb announces positive results from Phase 3 Poetyk PsA-1 and PsA-2 trials of deucravacitinib in psoriatic arthritis

Sun Pharma and Moebius Medical announce dual publications on MM-II’s phase 2b clinical trial results in Osteoarthritis and Cartilage

Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles

Sun Pharma and Moebius Medical granted FTD to MM-II for treatment of osteoarthritis knee pain

This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II

Ayurvedic Whole System effective in Managing Rheumatoid Arthritis: Study

The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention

LG Chem enters Chinese osteoarthritis treatment market

Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China

Shilpa Medicare receives USFDA approval for Psoriatic Arthritis Drug

Apremilast Tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene.